High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina
- PMID: 27068265
- DOI: 10.1038/tpj.2016.27
High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina
Abstract
A twofold higher frequency of CYP2D6 ultrarapid metabolizers (estimated from genotype: gUMs) was reported among Ashkenazi Jews (AJ) living in New York (USA) than in other North American Caucasians, which might be important to guide the prescription for CYP2D6 substrates in AJ communities around the world. This study was aimed to determine whether the high frequency of CYP2D6 gUMs described in AJ from USA was replicated in AJ from Argentina when compared with other multiethnic admixture Argentines (GA). The frequency of the most common allelic variants and of CYP2D6 gUMs (>2 active genes) and poor metabolizers (0 active genes, gPMs) was also compared among the studied Argentine populations. CYP2D6 genotyping was performed in 173 AJ and 246 GA DNA samples of unrelated donors from the metropolitan area of Buenos Aires. CYP2D6 alleles (*2, *3, *4, *5, *6, *10, *17, *35, *41 and multiple copies), genotypes and functional phenotype frequencies were determined. The frequencies of gUMs and gPMs in AJ from Argentina were 11.5% and 5.2%, respectively, whereas in GA, the frequencies of gUM and gPMs were 6.5% and 4.9%, respectively. Comparisons between AJ and GA showed that gUMs frequencies were twofold higher (P<0.05) in AJ than GA. CYP2D6*35 allele was more frequent in GA than AJ, whereas CYP2D6*41 and *1xN were more frequent in AJ than in GA (P<0.05). This study supports the previously reported high frequency of gUMs on another Ashkenazi population in New York. The present findings also support the interethnic variability of CYP2D6 genetic polymorphism in the overall Argentine population.
Similar articles
-
CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.Pharmacogenomics. 2007 Jul;8(7):721-30. doi: 10.2217/14622416.8.7.721. Pharmacogenomics. 2007. PMID: 18240905
-
Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations.Expert Opin Drug Metab Toxicol. 2014 Nov;10(11):1569-83. doi: 10.1517/17425255.2014.964204. Expert Opin Drug Metab Toxicol. 2014. PMID: 25316321 Review.
-
Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?Pharmacogenetics. 2001 Feb;11(1):45-55. doi: 10.1097/00008571-200102000-00006. Pharmacogenetics. 2001. PMID: 11207030
-
Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics.OMICS. 2018 Sep;22(9):575-588. doi: 10.1089/omi.2018.0114. Epub 2018 Sep 11. OMICS. 2018. PMID: 30183544
-
Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity.J Toxicol Environ Health B Crit Rev. 2009;12(5-6):334-61. doi: 10.1080/10937400903158342. J Toxicol Environ Health B Crit Rev. 2009. PMID: 20183526 Review.
Cited by
-
High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies.Pharmacogenomics J. 2016 Oct;16(5):485-90. doi: 10.1038/tpj.2016.47. Epub 2016 Jun 7. Pharmacogenomics J. 2016. PMID: 27272044
-
CYP2D6 and CYP2C19 Genes Associated with Tricontinental and Latin American Ancestry of Pe-ruvians.Drug Metab Bioanal Lett. 2022 Dec 13;16(1):14-26. doi: 10.2174/1872312815666221213151140. Online ahead of print. Drug Metab Bioanal Lett. 2022. PMID: 36518034 Free PMC article.
-
Relevance of CYP2D6 Gene Variants in Population Genetic Differentiation.Pharmaceutics. 2022 Nov 16;14(11):2481. doi: 10.3390/pharmaceutics14112481. Pharmaceutics. 2022. PMID: 36432672 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources